SCHEMBL6157005

SCHEMBL6157005

COc1ccc2c(c1OC)C(=O)NC2=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.53
NPC1 O15118 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
ALDH1A1 P00352 5/20 0.46
POLB P06746 2/20 0.46
GSK3B P49841 3/20 0.46
CDK4 P11802 2/20 0.46
CCND1 P24385 2/20 0.46
CCNA2 P20248 1/20 0.46
CDK2 P24941 1/20 0.46
CCNA1 P78396 1/20 0.46
KDM4E B2RXH2 4/20 0.46
HPGD P15428 1/20 0.46
LMNA P02545 1/20 0.44
HSD17B10 Q99714 2/20 0.43
USP8 P40818 1/20 0.43
USP7 Q93009 1/20 0.43
ACHE P22303 2/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11428923 0.80 GSK3B (0.45) RAB9AALDH1A1POLBGSK3BCDK4
SCHEMBL7964993 0.78 CA1 (0.56) RAB9ASMN1; SMN2ALDH1A1POLBGSK3B
SCHEMBL12253692 0.76 RAB9A (0.76) RAB9ANPC1SMN1; SMN2ALDH1A1POLB
SCHEMBL29378366 0.76 TOP1 (0.55) ALDH1A1GSK3BCDK4CCND1CCNA2
SCHEMBL384815 0.76 TOP1 (0.55) ALDH1A1GSK3BCDK4CCND1CCNA2
SCHEMBL30615182 0.73 L3MBTL1 (0.55) RAB9ANPC1SMN1; SMN2ALDH1A1POLB
SCHEMBL28149043 0.73 L3MBTL1 (0.55) RAB9ANPC1SMN1; SMN2ALDH1A1POLB
SCHEMBL2305964 0.73 RAB9A (0.47) RAB9ANPC1SMN1; SMN2ALDH1A1POLB
SCHEMBL1097120 0.73 L3MBTL1 (0.55) RAB9ANPC1SMN1; SMN2ALDH1A1POLB
SCHEMBL18170553 0.72 RAB9A (0.47) RAB9ANPC1SMN1; SMN2ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0856513-B1 Thalidomide analogues from the piperidine-2,6-dione class GRUENENTHAL GMBH (DE) 2005-11-30 EP claimed
EP-1575911-A2 BIAROMATIC COMPOUNDS WHICH ACTIVATE PPAR-GAMMA TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS Galderma Research & Development, S.N.C. (FR) 2005-09-21 EP claimed
WO-2004046091-A2 BIAROMATIC COMPOUNDS WHICH ACTIVATE PPAR-GAMA TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2004-06-03 WO claimed
US-6110941-A AN IMMUNOMODULATOR MODULATING THE IMMUNE RESPONSE OF A MAMMAL, INHIBITING ANTIGEN-INDUCED SYNTHESIS OF INTERLEUKIN-2 GRUENENTHAL GMBH (DE) 2000-08-29 US claimed
CN-1190096-A Compounds analogous to thalidomide from class comprising piperidine-2,6-diones GRUENENTHAL GMBH (DE) 1998-08-12 CN claimed
EP-0856513-A2 Thalidomide analogues from the piperidine-2,6-dione class Grünenthal GmbH (DE) 1998-08-05 EP claimed
US-20240246913-A1 2-CARBOXYL-INDOLE INHIBITORS OF METALLO-BETA-LACTAMASES OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2024-07-25 US disclosed
EP-4347563-A1 2-CARBOXYL-INDOLE INHIBITORS OF METALLO-BETA-LACTAMASES Oxford University Innovation Limited (GB) 2024-04-10 EP disclosed
CN-117677606-A 2-carboxy-indole inhibitors of metallo-beta-lactamase 牛津大学创新有限公司 2024-03-08 CN disclosed
WO-2022248887-A1 2-CARBOXYL-INDOLE INHIBITORS OF METALLO-BETA-LACTAMASES OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2022-12-01 WO disclosed
EP-0856513-B1 Thalidomide analogues from the piperidine-2,6-dione class GRUENENTHAL GMBH (DE) 2005-11-30 EP disclosed
EP-1575911-A2 BIAROMATIC COMPOUNDS WHICH ACTIVATE PPAR-GAMMA TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS Galderma Research & Development, S.N.C. (FR) 2005-09-21 EP disclosed
WO-2004046091-A2 BIAROMATIC COMPOUNDS WHICH ACTIVATE PPAR-GAMA TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2004-06-03 WO disclosed
US-6110941-A AN IMMUNOMODULATOR MODULATING THE IMMUNE RESPONSE OF A MAMMAL, INHIBITING ANTIGEN-INDUCED SYNTHESIS OF INTERLEUKIN-2 GRUENENTHAL GMBH (DE) 2000-08-29 US disclosed
EP-0856513-A2 Thalidomide analogues from the piperidine-2,6-dione class Grünenthal GmbH (DE) 1998-08-05 EP disclosed
EP-0412763-B1 Cephalosporins, processes for their preparation, pharmaceutical compositions containing them and intermediates therefor ZENECA LTD (GB) 1996-07-10 EP disclosed
US-5219848-A Bactericides ICI PHARMA (FR) 1993-06-15 US disclosed
EP-0412763-A2 Cephalosporins, processes for their preparation, pharmaceutical compositions containing them and intermediates therefor ZENECA LIMITED (GB) 1991-02-13 EP disclosed
US-4144072-A CONTAINING A PHTHALAZINONE AND A PHTHALIMIDE FUJI PHOTO FILM CO., LTD. (JP) 1979-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240246913-A1 2-CARBOXYL-INDOLE INHIBITORS OF METALLO-BETA-LACTAMASES IDO2, IDO1, COMT RAB9A 2679/4885NPC1 3704/4885SMN1; SMN2 4150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.